TOXICOLOGICAL HIGHLIGHT |
The TRPV1 Receptor: Target of Toxicants and Therapeutics

* National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Neurotoxicology DivisionCellular and Molecular Branch, Mail Drop B10506, Research Triangle Park, North Carolina 27711, and
Cato Research Ltd., Integrated Drug Development, Durham, North Carolina 27713
Received October 27, 2005; accepted October 28, 2005
ABSTRACT
Understanding the structural and functional complexities of the transient receptor potential vanilloid receptor (TRPV1) is essential to the therapeutic modulation of inflammation and pain. Because of its central role in initiating inflammatory processes and integrating painful stimuli, there is an understandable interest in its pharmacological manipulation (sensitization/desensitization). The present Highlight entitled "TRPV1 antagonists elevate cell surface populations of receptor protein and exacerbate TRPV1 mediated toxicities in human lung epithelial cells" describes how exposure to various antagonists produces TRPV1 sensitization and proposes a possible mechanistic explanation to that sensitization.
Key Words: TRPV1; capsaicin receptor; neurogenic inflammation; respiratory inflammation; BEAS-2B; particulate matter.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. Marincsak, B. I. Toth, G. Czifra, T. Szabo, L. Kovacs, and T. Biro The Analgesic Drug, Tramadol, Acts as an Agonist of the Transient Receptor Potential Vanilloid-1 Anesth. Analg., June 1, 2008; 106(6): 1890 - 1896. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Silver, T. R. Clapp, L. M. Stone, and S. C. Kinnamon TRPV1 Receptors and Nasal Trigeminal Chemesthesis Chem Senses, November 1, 2006; 31(9): 807 - 812. [Abstract] [Full Text] [PDF] |
||||

